Evolent Health Inc (NYSE:EVH) has been assigned a consensus recommendation of “Buy” from the nine brokerages that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $16.75.
EVH has been the topic of several analyst reports. Piper Jaffray Companies set a $10.00 target price on Evolent Health and gave the stock a “buy” rating in a report on Tuesday, September 10th. Cantor Fitzgerald set a $16.00 target price on Evolent Health and gave the stock an “overweight” rating in a report on Wednesday, August 7th. ValuEngine raised Evolent Health from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research lowered Evolent Health from a “buy” rating to a “hold” rating in a report on Tuesday, August 6th. Finally, Oppenheimer set a $15.00 target price on Evolent Health and gave the stock a “buy” rating in a report on Wednesday, August 7th.
Shares of EVH stock traded up $0.08 during mid-day trading on Monday, reaching $7.54. The stock had a trading volume of 675,400 shares, compared to its average volume of 1,375,550. The business’s fifty day moving average is $7.39 and its 200-day moving average is $9.23. The company has a current ratio of 1.39, a quick ratio of 1.39 and a debt-to-equity ratio of 0.26. The firm has a market cap of $637.27 million, a price-to-earnings ratio of -21.54 and a beta of 1.06. Evolent Health has a 1-year low of $5.50 and a 1-year high of $26.96.
Evolent Health (NYSE:EVH) last announced its quarterly earnings data on Tuesday, August 6th. The technology company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.03. The business had revenue of $192.00 million for the quarter, compared to analyst estimates of $192.51 million. Evolent Health had a negative return on equity of 6.47% and a negative net margin of 14.67%. The company’s revenue was up 33.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.03) earnings per share. On average, analysts forecast that Evolent Health will post -0.96 earnings per share for the current year.
In other Evolent Health news, Director Michael D’amato purchased 15,000 shares of the stock in a transaction on Friday, August 9th. The shares were bought at an average price of $7.03 per share, for a total transaction of $105,450.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Doug S. Aron purchased 10,550 shares of the stock in a transaction on Wednesday, August 14th. The shares were acquired at an average price of $8.20 per share, for a total transaction of $86,510.00. Over the last ninety days, insiders have purchased 32,750 shares of company stock worth $242,648. 4.50% of the stock is owned by corporate insiders.
Hedge funds have recently modified their holdings of the business. Northern Trust Corp boosted its position in Evolent Health by 0.9% during the second quarter. Northern Trust Corp now owns 1,017,149 shares of the technology company’s stock worth $8,086,000 after purchasing an additional 9,393 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its position in Evolent Health by 94.4% during the second quarter. DekaBank Deutsche Girozentrale now owns 12,061 shares of the technology company’s stock worth $95,000 after purchasing an additional 5,856 shares in the last quarter. Conestoga Capital Advisors LLC boosted its position in Evolent Health by 36.2% during the second quarter. Conestoga Capital Advisors LLC now owns 30,390 shares of the technology company’s stock worth $242,000 after purchasing an additional 8,070 shares in the last quarter. Aperio Group LLC purchased a new position in Evolent Health during the second quarter worth approximately $40,000. Finally, Marshall Wace LLP boosted its position in Evolent Health by 110.0% during the second quarter. Marshall Wace LLP now owns 1,613,272 shares of the technology company’s stock worth $12,825,000 after purchasing an additional 844,888 shares in the last quarter. Institutional investors own 94.33% of the company’s stock.
Evolent Health Company Profile
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Read More: What is a bull market?
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.